Supermax BhdXKLS:7106 51 EBITDA Margin % is -29.86% as of Mar. 2026. GuruFocus rates XKLS:7106 with a GF Score™ of 51/100 and a GF Value™ of RM0.68 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Supermax Bhd ranks worse than 78.31% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Supermax Bhd's EBITDA for the
three
months ended in Mar. 2026 was RM-37.8 Mil. Supermax Bhd's Revenue for the
three
months ended in Mar. 2026 was RM126.8 Mil. Therefore, Supermax Bhd's EBITDA margin for the quarter that ended in Mar. 2026 was -29.86%.
Supermax Bhd (XKLS:7106) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Supermax Bhd EBITDA Margin % Related Terms
Supermax Bhd EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Supermax Bhd's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7106 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Supermax Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supermax Bhd EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Supermax Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Supermax Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supermax Bhd (XKLS:7106) has a EBITDA Margin % of -29.86% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Supermax Bhd and its competitors. According to the industry distribution chart, Supermax Bhd ranks #639 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 78.3%.
Is Supermax Bhd's EBITDA Margin % too high?
Supermax Bhd's current EBITDA Margin % is -29.86%. Based on the distribution chart, Supermax Bhd ranks #639 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Supermax Bhd has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Supermax Bhd's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Supermax Bhd ranks #639 out of 816 companies for EBITDA Margin %. This places Supermax Bhd in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Supermax Bhd and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supermax Bhd's current EBITDA Margin % is -29.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supermax Bhd stock overvalued right now?
Based on GuruFocus' analysis, Supermax Bhd (XKLS:7106) is currently considered Possible Value Trap. The stock's GF Value™ is RM0.68, compared to a current price of RM0.28 — trading 59.6% below its estimated fair value. The current EBITDA Margin % is -29.86%. Supermax Bhd's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Supermax Bhd (XKLS:7106), the current EBITDA Margin % is -29.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supermax Bhd (XKLS:7106) Overvalued in 2026?
Based on GuruFocus' analysis, Supermax Bhd stock appears to be undervalued.
The current stock price of RM0.28 is trading 59.6% below its estimated GF Value™ of RM0.68.
GuruFocus considers Supermax Bhd to be Possible Value Trap.
Key valuation signals for XKLS:7106:
EBITDA Margin %: -29.86%
GF Value™: RM0.68 vs. price of RM0.28 (59.6% below fair value)
No single metric tells the full story. See the XKLS:7106 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supermax Corp Bhd is an investment holding company. Along with its subsidiaries, the company operates as an international manufacturer, distributor, and marketer of high-quality medical gloves and contact lenses. It offers various types of latex gloves, which are exported to numerous countries. The company is organized into the following reportable operating segments: manufacturing of gloves, which generates the majority of revenue; investment holding; trading of gloves; and others. Geographically, it derives the majority of its revenue from Europe, with the remainder coming from Africa, Asia and Oceania, and North, Central, and South America.
51GF Score
Get the complete analysis for XKLS:7106
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7106 has been successfully added to your 
